Evidence map›Paper›PMID 41062549›Full record

ArticleScientific reports2025

A systematic comparison of CRISPR-Cas9 allele editing in Candida auris demonstrates unreliable cassette integration and effective episomal plasmid-based editing.

Dimitrios Sofras, Hans Carolus, Ana Subotić, Celia Lobo Romero, Craig L Ennis, Lize Cuypers, Katrien Lagrou, Aaron D Hernday, Clarissa J Nobile, Jeffrey M Rybak and 1 more

Abstract readComparative Study
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Defining thebioRxiv : the preprint server for biology · 2026
    Article
  3. EditingBiomolecules · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dimitrios Sofras *Laboratory of Molecular Cell Biology, Department of Biology, KU Leuven, Leuven, Belgium.
Hans Carolus *Laboratory of Molecular Cell Biology, Department of Biology, KU Leuven, Leuven, Belgium. hans.carolus@kuleuven.be.
Ana SubotićLaboratory of Molecular Cell Biology, Department of Biology, KU Leuven, Leuven, Belgium.
Celia Lobo RomeroLaboratory of Molecular Cell Biology, Department of Biology, KU Leuven, Leuven, Belgium.
Craig L EnnisDepartment of Molecular and Cell Biology, School of Natural Sciences, University of California Merced, Merced, CA, USA.
Lize CuypersLaboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Katrien LagrouLaboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Aaron D HerndayDepartment of Molecular and Cell Biology, School of Natural Sciences, University of California Merced, Merced, CA, USA.
Clarissa J NobileDepartment of Molecular and Cell Biology, School of Natural Sciences, University of California Merced, Merced, CA, USA.
Jeffrey M RybakSt. Jude Children's Research Hospital, Memphis, TN, USA. jeffrey.rybak@stjude.org.
Patrick Van DijckLaboratory of Molecular Cell Biology, Department of Biology, KU Leuven, Leuven, Belgium. patrick.vandijck@kuleuven.be.

Funding

Genetic regulation of inter- and intra-species microbial community formationR35GM124594 · NIGMS · UNIVERSITY OF CALIFORNIA, MERCED · PI NOBILE, CLARISSA JANE · 2017 to 2021
$2.0M
Genetic regulation of antifungal drug resistance in Candida albicansF31DE028488 · NIDCR · UNIVERSITY OF CALIFORNIA, MERCED · PI ENNIS, CRAIG LEWIS · 2019 to 2021
$101k
Fonds Wetenschappelijk Onderzoek 11D7620NFonds Wetenschappelijk Onderzoek 11J8122NJoint Programming Initiative on Antimicrobial Resistance G0L1622NNIDCR NIH HHS F31 DE028488NIDCR NIH HHS F31DE028488NIGMS NIH HHS R35 GM124594NIGMS NIH HHS R35GM124594Onderzoeksraad, KU Leuven C3/22/007Onderzoeksraad, KU Leuven PDMT2/23/032
6 · The paper itself

Abstract

Candidozyma (Candida) auris is an emergent fungal pathogen of significant interest for molecular research. A handful of CRISPR-Cas9 based allele editing tools have been optimized for C. auris. Nonetheless, allele editing in this species remains a significant challenge, and different systems have different advantages and disadvantages. In this work, we compare four systems to introduce the genetic elements necessary for the production of Cas9 and the guide RNA molecule in the genome of C. auris, replacing the ENO1, LEU2 and HIS1 loci respectively, while the fourth system makes use of an episomal plasmid. We observed that the editing efficiency of all four systems was significantly different and strain-dependent. However, we did not detect correct integration of linear CRISPR cassette constructs in integration-based systems, in over 4,900 screened transformants. Still, all transformants, whether correctly edited or not, grew on selective nourseothricin media, suggesting ectopic integration of the CRISPR cassette, which was confirmed by long-read whole genome sequencing. The plasmid-based system showed the highest editing efficiency with an average of 41.9% correct transformants, despite yielding fewer transformants compared to the other systems. Transformation of protoplasts or silencing the non-homologous end joining (NHEJ) DNA repair pathway, by deleting two main NHEJ factors, KU70 and LIG4, did not improve the editing efficiency. While our research highlights important challenges in precise genome editing of C. auris by quantitatively evaluating the editing and targeting efficiencies of different methods, it also clearly shows the safety and usefulness of plasmid-based systems like EPIC, which we recommend for molecular work in this enigmatic fungal pathogen.

Indexed as

Candida aurisCRISPR-Cas SystemsGene EditingPlasmidsAllelesGenome, FungalRNA, Guide, CRISPR-Cas SystemsRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID41062549
PMCPMC12508224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.